ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Treatment-free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia and Stable Deep Molecular Response Discontinuing Dasatinib (DASFREE)

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Susanne Saussele
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Susanne Saussele
21 views
January 2, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Scientific Session 7: Treatment-free Remission
12:56
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time…

Feat. D. Kim
18:28
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

What Prevents the Disease from Relapsing after TKI Discontinuation

Feat. S. Mustjoki
11:10
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Treatment-free Remission in Patients with Chronic Phase Chronic Myel…

Feat. S. Saussele